Intellia’s Lonvo-z Cuts HAE Attacks by 89%, Preps 2027 Launch
NTLA•In Phase 3 Haelo trial, a single dose of Lonvo-z reduced rescue-medication–required HAE attacks by 89% and moderate-to-severe attacks by 91%, with quality-of-life scores rising over 17 points versus placebo. Intellia has initiated its rolling FDA biologics license application and aims for a first-half 2027 U.S. launch.
1. Haelo Trial Efficacy
In its Phase 3 Haelo trial, a single dose of Lonvo-z reduced attacks requiring rescue medication by 89% and moderate-to-severe attacks by 91%, exceeding primary endpoints.
2. Quality-of-Life and Biomarker Outcomes
Patients treated with Lonvo-z experienced mean quality-of-life score improvements over 17 points versus placebo and sustained plasma kallikrein suppression from day 15 through the latest data cutoff.
3. Regulatory Pathway
Intellia has initiated a rolling biologics license application with FDA and maintains its goal of U.S. approval and launch in the first half of 2027.
4. Market Reaction and Outlook
Shares rose about 5% premarket following the data release, rebounding from an 11% drop the prior week, as investors priced in potential approval of the first in vivo CRISPR therapy.
